Please ensure Javascript is enabled for purposes of website accessibility

This Falling Scalpel Could Cut You

By Dave Williamson – Updated Apr 7, 2017 at 12:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In this video, health-care analysts David Williamson and Max Macaluso discuss the recent 20% plunge suffered by Edwards Lifesciences investors and whether the factors behind the substantial revenue miss make the stock a bad news buy or if investors will be cut trying to catch a falling knife.

We all would like to build long-term wealth and retire well, but buying stocks after a sudden plunge isn't a surefire strategy. In our free report "3 Stocks That Will Help You Retire Rich," we reveal some stocks that could help you as well as some winning wealth-building strategies. Click here to keep reading.

Dave Williamson and Max Macaluso have no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and St. Jude Medical. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.